AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events
by Yiming Li, Jianfu Li, Jianping He, Cui Tao
Though Vaccines are instrumental in global health, mitigating infectious diseases and pandemic outbreaks, they can occasionally lead to adverse events (AEs). Recently, Large Language Models (LLMs) have shown promise in effectively identifying and cataloging AEs within clinical reports. Utilizing d ata from the Vaccine Adverse Event Reporting System (VAERS) from 1990 to 2016, this study particularly focuses on AEs to evaluate LLMs’ capability for AE extraction. A variety of prevalent LLMs, including GPT-2, GPT-3 variants, GPT-4, and Llama2, were evaluated using Influenza vacc...
Source: PLoS One - March 21, 2024 Category: Biomedical Science Authors: Yiming Li Source Type: research
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - March 21, 2024 Category: Allergy & Immunology Authors: Abdi NaficyAdrienne KuxhausenHarry SeifertAndrew HastieBrett LeavJacqueline MillerKate AnteyiAgnes Mwakingwe-Omaria GSK, Rockville, MD, USAb Moderna, Inc, Cambridge, MA, USA Source Type: research
Does the Australian influenza season predict the Canadian influenza season? A qualitative comparison of seasons, 2014-2020
Can Commun Dis Rep. 2023 Nov 1;49(11-12):494-500. doi: 10.14745/ccdr.v49i1112a05. eCollection 2023 Nov 1.ABSTRACTA commonly held belief by the Canadian media and public is that the Australian influenza season is a fairly reliable indicator of what the Canadian influenza season that follows might be like. However, this claim is not well substantiated with epidemiological evidence. Therefore, the objective of this work was to qualitatively compare the timing of the onset, peak, and intensity of influenza activity, the dominant circulating influenza strains, and the seasonal vaccine and vaccination policies from 2014 to 2020 ...
Source: Can Commun Dis Rep - March 20, 2024 Category: Infectious Diseases Authors: Deborah Chan Liza Lee Christina Bancej Source Type: research
Does the Australian influenza season predict the Canadian influenza season? A qualitative comparison of seasons, 2014-2020
Can Commun Dis Rep. 2023 Nov 1;49(11-12):494-500. doi: 10.14745/ccdr.v49i1112a05. eCollection 2023 Nov 1.ABSTRACTA commonly held belief by the Canadian media and public is that the Australian influenza season is a fairly reliable indicator of what the Canadian influenza season that follows might be like. However, this claim is not well substantiated with epidemiological evidence. Therefore, the objective of this work was to qualitatively compare the timing of the onset, peak, and intensity of influenza activity, the dominant circulating influenza strains, and the seasonal vaccine and vaccination policies from 2014 to 2020 ...
Source: Can Commun Dis Rep - March 20, 2024 Category: Infectious Diseases Authors: Deborah Chan Liza Lee Christina Bancej Source Type: research
Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge
Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.03.040. Online ahead of print.ABSTRACTThe COVID-19 pandemic has highlighted the need for mucosal vaccines as breakthrough infections, short-lived immune responses and emergence of new variants have challenged the efficacy provided by the first generation of vaccines against SARS-CoV-2 viruses. M2SR SARS-CoV-2, an M2-deleted single-replication influenza virus vector modified to encode the SARS-CoV-2 receptor binding domain, was evaluated following intranasal delivery in a hamster challenge model for protection against Wuhan SARS-CoV-2. An adjuvanted ina...
Source: Vaccine - March 20, 2024 Category: Allergy & Immunology Authors: Lindsay Hill-Batorski Richard Bowen Helle Bielefeldt-Ohmann Michael J Moser Sarah M Matejka David Marshall Yoshihiro Kawaoka Gabriele Neumann Pamuk Bilsel Source Type: research
Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity
Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.11.057. Online ahead of print.ABSTRACTThe development of an effective combined vaccine represents a crucial strategy for preventing outbreaks of infectious diseases and reducing the burden on healthcare resources. Developing a combined vaccine against both influenza and the coronavirus is a promising approach, but it is still in the early stages of development. This paper reports on a novel combined pentavalent candidate vaccine that has shown promising results in mice, with statistically significant differences in mean antibody titer against the coron...
Source: Vaccine - March 20, 2024 Category: Allergy & Immunology Authors: Igor Krasilnikov Artur Isaev Milana Djonovic Alexander Ivanov Ekaterina Romanovskaya-Romanko Marina Stukova Vitaly Zverev Source Type: research
Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2
In this study, neutralizing breadth and antigen-specific CD8+ T cell responses were analyzed in both infection-naïve and infection-experienced individuals following administration of a booster bivalent Wuhan-Hu-1+BA.4/5 Comirnaty® mRNA vaccine. Significantly higher neutralizing titers were found after this vaccination compared to the pre-third booster vaccination time point. Further, neutralizing breadth to omicron variants, including BA.1, BA.2, BA.5, BQ.1 and XBB.1, was found to be boosted following bivalent vaccination. SARS-CoV-2-specific CD8+ T cells were identified, but with no evidence that frequencies were increa...
Source: Frontiers in Immunology - March 20, 2024 Category: Allergy & Immunology Source Type: research
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
ConclusionsThese findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged ≥ 60 years. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - March 20, 2024 Category: Infectious Diseases Source Type: research
Return to flying duties of German military pilots after recovery from COVID-19
Conclusion
Due to their demanding working environment, pilots, and other high-hazard employees, should undergo medical evaluation prior to return to their duties to exclude ongoing symptoms and the development of post-acute COVID-19 or post-COVID-19 syndrome. The scope of examinations may depend on the severity of the disease, comorbidities, the vaccination status, the predominant SARS-CoV-2 variant and the type of aircraft flown. (Source: Journal of the Royal Army Medical Corps)
Source: Journal of the Royal Army Medical Corps - March 20, 2024 Category: General Medicine Authors: Adam, T., Sammito, S., Nicol, E., Guettler, N. J. Tags: COVID-19 Original research Source Type: research
A computational approach to design a multiepitope vaccine against H5N1 virus
Since 1997, highly pathogenic avian influenza viruses, such as H5N1, have been recognized as a possible pandemic hazard to men and the poultry business. The rapid rate of mutation of H5N1 viruses makes the who... (Source: Virology Journal)
Source: Virology Journal - March 20, 2024 Category: Virology Authors: Fatemeh Dashti, Arash Raisi, Ghazaleh Pourali, Zahra Sadat Razavi, Fatemeh Ravaei, Javid Sadri Nahand, Fatemeh Kourkinejad-Gharaei, Seyed Mohammad Ali Mirazimi, Javad Zamani, Hossein Tarrahimofrad, Seyed Mohammad Reza Hashemian and Hamed Mirzaei Tags: Research Source Type: research
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
ConclusionsThese findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged ≥ 60 years. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - March 20, 2024 Category: Infectious Diseases Source Type: research
Predictors of seasonal influenza and COVID-19 vaccination coverage among adults in Tennessee during the COVID-19 pandemic
CONCLUSION: Strategies to increase COVID-19 and influenza vaccination should be age-specific, focus on increasing geographical and financial access, and offer tailored messages to address concerns about these vaccines.PMID:38500722 | PMC:PMC10945017 | DOI:10.3389/fpubh.2024.1321173 (Source: Cancer Control)
Source: Cancer Control - March 19, 2024 Category: Cancer & Oncology Authors: J Cunningham-Erves W George M Sanderson E Stewart S W Jin J Davis H M Brandt Source Type: research
Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines: a discrete-choice experiment
CONCLUSION: Hib seroprotection at 11-12 months was the most important hexavalent vaccine attribute to HCPs in this study.PMID:38501272 | DOI:10.1080/03007995.2024.2325550 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 19, 2024 Category: Research Authors: Salome Samant Susanne Oberle Tomas Marcek Christine Poulos Phani Chintakayala Edith Langevin Tanaz Petigara Marco Boeri Source Type: research
Stroke Risk After COVID-19 Bivalent Vaccination in US Older Adults
This self-controlled case series evaluates stroke risk after administration of either brand of the COVID-19 bivalent vaccine, either brand of the COVID-19 bivalent plus a high-dose or adjuvanted influenza vaccine on the same day, and a high-dose or adjuvanted influenza vaccine in Medicare beneficiaries aged 65 years or older. (Source: JAMA)
Source: JAMA - March 19, 2024 Category: General Medicine Source Type: research
Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial
CONCLUSION: In a prespecified exploratory analysis, modest increases in influenza vaccination rates seen with electronic nudges did not translate into observable improvements in clinical outcomes. Seasonal influenza vaccination should remain strongly recommended.PRIMARY FUNDING SOURCE: Sanofi.PMID:38498876 | DOI:10.7326/M23-2638 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 18, 2024 Category: Internal Medicine Authors: Niklas Dyrby Johansen Muthiah Vaduganathan Ankeet S Bhatt Simin Gharib Lee Daniel Modin Brian L Claggett Erica L Dueger Sandrine Samson Matthew M Loiacono Rebecca C Harris Lars K øber Scott D Solomon Pradeesh Sivapalan Jens Ulrik St æhr Jensen Cyril Jea Source Type: research
